LH WI — Laboratory of America Holdings Share Price
Last trade - 00:00- $18.51bn
- $23.58bn
- $14.88bn
- 81
- 71
- 75
- 89
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.65 | ||
| PEG Ratio (f) | 2.64 | ||
| EPS Growth (f) | 4.61% | ||
| Dividend Yield (f) | 1.41% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.79 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 14.66 | ||
| Price to Sales | 1.25 | ||
| EV to EBITDA | 11.42 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.24% | ||
| Return on Equity | 9.5% | ||
| Operating Margin | 9.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11,333.4 | 11,554.8 | 13,978.5 | 16,120.9 | 14,876.8 | 15,221.51 | 15,936.7 | 7.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +40.83 | -6.47 | +103.26 | +29.43 | -32.09 | -0.97 | +10.1 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. The Company’s segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
Directors
- Adam Schechter PRE (56)
- Glenn Eisenberg CFO (60)
- Judith Seltz CHO (58)
- Lance Berberian EVP (58)
- Amy Summy EVP (55)
- Sandra Van Der Vaart EVP (61)
- Brian Caveney EVP (47)
- Paul Kirchgraber EVP (59)
- Mark Schroeder EVP (60)
- Peter Wilkinson SVP (50)
- Peter Neupert LED (65)
- Kerrii Anderson IND (64)
- Jean-Luc Belingard IND (72)
- Jeffrey Davis IND (57)
- D. Gary Gilliland IND (66)
- Garheng Kong IND (45)
- Richelle Parham IND (53)
- Kathryn Wengel IND (55)
- Robert Williams IND (72)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- March 8th, 1994
- Public Since
- April 24th, 1991
- No. of Shareholders
- 1,249
- No. of Employees
- 80,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 88,600,000
- Address
- 358 S MAIN ST, BURLINGTON, 27215-5837
- Web
- https://www.labcorp.com
- Phone
- +1 3362291127
- Contact
- Chas Cook
- Auditors
- PricewaterhouseCoopers LLP
Latest News for LH WI
Similar to LH WI
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ardent Health Partners LLC
New York Stock Exchange
Ati Physical Therapy
New York Stock Exchange
FAQ
As of Today at 01:13 UTC, shares in Laboratory of America Holdings are trading at $207.45. This share price information is delayed by 15 minutes.
Shares in Laboratory of America Holdings last closed at $207.45 and the price had moved by over the past 365 days. In terms of relative price strength the Laboratory of America Holdings share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for Laboratory of America Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Laboratory of America Holdings does not currently pay a dividend.
Laboratory of America Holdings does not currently pay a dividend.
Laboratory of America Holdings does not currently pay a dividend.
To buy shares in Laboratory of America Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $207.45, shares in Laboratory of America Holdings had a market capitalisation of $18.51bn.
Here are the trading details for Laboratory of America Holdings:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: LH WI
Based on an overall assessment of its quality, value and momentum Laboratory of America Holdings is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Laboratory of America Holdings is $271.15. That is 30.71% above the last closing price of $207.45.
Analysts covering Laboratory of America Holdings currently have a consensus Earnings Per Share (EPS) forecast of $16.94 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Laboratory of America Holdings. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $207.45, shares in Laboratory of America Holdings were trading +1.87% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Laboratory of America Holdings PE ratio based on its reported earnings over the past 12 months is 11.65. The shares last closed at $207.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Laboratory of America Holdings' management team is headed by:
- Adam Schechter - PRE
- Glenn Eisenberg - CFO
- Judith Seltz - CHO
- Lance Berberian - EVP
- Amy Summy - EVP
- Sandra Van Der Vaart - EVP
- Brian Caveney - EVP
- Paul Kirchgraber - EVP
- Mark Schroeder - EVP
- Peter Wilkinson - SVP
- Peter Neupert - LED
- Kerrii Anderson - IND
- Jean-Luc Belingard - IND
- Jeffrey Davis - IND
- D. Gary Gilliland - IND
- Garheng Kong - IND
- Richelle Parham - IND
- Kathryn Wengel - IND
- Robert Williams - IND